

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4579164/publications.pdf>

Version: 2024-02-01

22
papers

1,142
citations

516710

16
h-index

677142

22
g-index

22
all docs

22
docs citations

22
times ranked

2618
citing authors

#	ARTICLE	IF	CITATIONS
1	Full Activation of PKB/Akt in Response to Insulin or Ionizing Radiation Is Mediated through ATM. <i>Journal of Biological Chemistry</i> , 2005, 280, 4029-4036.	3.4	231
2	Role of the p38 MAPK pathway in cisplatin-based therapy. <i>Oncogene</i> , 2003, 22, 3998-4006.	5.9	148
3	Regulation of p73 by c-Abl through the p38 MAP kinase pathway. <i>Oncogene</i> , 2002, 21, 974-979.	5.9	105
4	BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis. <i>Nature Communications</i> , 2016, 7, 10153.	12.8	104
5	Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas. <i>Nature</i> , 2018, 554, 533-537.	27.8	101
6	RAB7 Controls Melanoma Progression by Exploiting a Lineage-Specific Wiring of the Endolysosomal Pathway. <i>Cancer Cell</i> , 2014, 26, 61-76.	16.8	86
7	Sirtuin-1 Regulates Acinar-to-Ductal Metaplasia and Supports Cancer Cell Viability in Pancreatic Cancer. <i>Cancer Research</i> , 2013, 73, 2357-2367.	0.9	59
8	Ribonucleoprotein HNRNPA2B1 Interacts With and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells. <i>Gastroenterology</i> , 2014, 147, 882-892.e8.	1.3	56
9	Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin. <i>Oncogene</i> , 2002, 21, 7131-7136.	5.9	41
10	Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. <i>International Journal of Cancer</i> , 2006, 119, 455-462.	5.1	30
11	Dual regulation of Myc by Abl. <i>Oncogene</i> , 2013, 32, 5261-5271.	5.9	26
12	Choline Kinase Alpha (CHK1±) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 323-333.	4.1	25
13	MYC degradation: deubiquitinating enzymes enter the dance. <i>Nature Cell Biology</i> , 2007, 9, 729-731.	10.3	23
14	c-MYC partners with BPTF in human cancer. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1152346.	0.7	23
15	Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. <i>Biochemical Journal</i> , 2005, 387, 231-238.	3.7	22
16	c-Myc downregulation is required for preacinar to acinar maturation and pancreatic homeostasis. <i>Gut</i> , 2017, 67, gutjnl-2016-312306.	12.1	18
17	Mnk1 is a novel acinar cell-specific kinase required for exocrine pancreatic secretion and response to pancreatitis in mice. <i>Gut</i> , 2015, 64, 937-947.	12.1	13
18	Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system. <i>Cancer Gene Therapy</i> , 2003, 10, 152-160.	4.6	10

#	ARTICLE	IF	CITATIONS
19	ICAT is a novel Ptf1a interactor that regulates pancreatic acinar differentiation and displays altered expression in tumours. <i>Biochemical Journal</i> , 2013, 451, 395-405.	3.7	6
20	The Role of the Proto-Oncogene c-myc in B Lymphocyte Differentiation. <i>Critical Reviews in Immunology</i> , 2012, 32, 321-334.	0.5	6
21	Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2077.	4.1	5
22	Targeting BPTF Sensitizes Pancreatic Ductal Adenocarcinoma to Chemotherapy by Repressing ABC-Transporters and Impairing Multidrug Resistance (MDR). <i>Cancers</i> , 2022, 14, 1518.	3.7	4